Memo Therapeutics, a Basel/Zurich-based developer of a platform technology for antibody discovery, closed a CHF2.3m Series A financing.
The round by Redalpine and other Swiss investors, including EVA Basel and Zürcher Kantonalbank.
The company intends to use the funds to further develop and validate its MemoMABTM antibody discovery platform.
A spin-off company from the ETH Zurich, Memo Therapeutics allows banking and mining the complete ”antibodyome” – the entire antibody repertoire of human and animal species. Its MemoMAB utilizes nanoliter reactor technology to increase throughput and performance of biological assays.